-
Tea is a good medicine guide
Time of Update: 2021-01-22
some traditional Chinese medicine treatment, and sometimes also instructed to use warm black tea delivery. Many patients will be confused: the drug is not the best warm water, tea will not affect the effectiveness of the drug? tea does have
-
Treatment of schizophrenia, the first pure "domestic medicine" came
Time of Update: 2021-01-22
in schizophrenia patients on the long prescription list, "purely domestic" absent, "foreign technology" has become the main character. Now, the good news is coming. In mid-January, china's first independent research and development
-
The results of the work of the team of medicinal bacteria in Hubei Academy of Agricultural Sciences
Time of Update: 2021-01-22
the transformation and application of results In 2020, the team has four patent transfers, among which "a method for preparing high-fold brewing pulp with deep fermentation solution of black wood ears" and "a method for preparing health-care rice
-
Kang Caixin | approved Huaxi bio-surge Jin live medicine overseas flagship store will be launched
Time of Update: 2021-01-22
qualification audit has been completed, and the flagship store is expected to be officially launched by the end of January 2021. flagship store will be operated by Jin live Pharmaceuticals Health Development Co., Ltd., a whowed subsidiary of the company
-
Drug patent attack and defense strength ranked: Hengrui, Tianqing, stone medicine ranked in the top three
Time of Update: 2021-01-21
of the wind", and "patent quality" is the key to win the patent attack and defense war. years, the major domestic innovative pharmaceutical companies not only strengthen their own patent layout, but also in order to seize the market opportunity, have
-
Domestic kinase inhibitors enter the international market! And yellow medicine Sovantini
Time of Update: 2021-01-21
And Huang China Pharmaceutical Technology Co., Ltd. ("and Yellow Pharma" or "Chi-Med") recently announced that it has begun rolling the submission to the U.S. Food and Drug Administration (FDA) of the first part of the new drug listing application
-
A batch of Chinese medicine into the protection of Chinese medicine varieties, extend the protection period!
Time of Update: 2021-01-21
provisions of the Regulations on the Protection of Chinese Medicines, the cough control produced by the Sixth Chinese Medicine Factory of Tianjin China New Pharmaceutical Group Co., Ltd. has been reviewed by the members of the Committee for the Protection
-
The first 10 months by the CDE priority review of 40 enterprises involving Hengrui, Junshi, stone medicine....
Time of Update: 2021-01-21
details of the priority review of biopharmaceons and Class 1 chemicals for domestic enterprises, as shown in the table below.
-
And platinum medicine CTLA-4 monoantigen HBM4003 initiated a Phase I clinical
Time of Update: 2021-01-21
On January 7, Insight database showed that CTLA-4 monoantibodies HBM4003 of Platinum Pharmaceuticals initiated a Phase I clinical trial for advanced solid tumors.
-
Publicity of the proposed list of recommendations for the second batch of incentives for generic medicines
Time of Update: 2021-01-21
/>: 010-68792519 Fax: 010-68792819 E-mail: yzsmlc@nhc.gov.cn Feedback deadline is January 7, 2021. : List of recommendations for the second batch of recommendations to encourage generic medicines National Health And Human Services Commission, 30 December 2020
-
2020 Final Inventory: Interpretation of the Nobel Prize in Physiology and Medicine
Time of Update: 2021-01-21
the Distinguished Canadian Geldner International Award for his important contribution to the detection and isolation of the hepatitis C virus8. Michael Houghton was born in the UK. received his Ph.D. from King's College London in 1977
-
Domestic kinase inhibitors! And yellow medicine Sofantini (Sutaida®) approved by the State Drug
Time of Update: 2021-01-20
("and Huang Medicine" or "Chi-Med") recently announced that Sovantini (Chinese trade name: Sutaida ®) has been officially approved by China's State Drug Administration (NMPA) for the treatment of non-pancreatic neuroendocrine tumors (NET).
-
New migraine medicine! Lingbei CGRP targeted antibody Vyepti entered the EU review: the first day of effective, 4 times a year intravenous dosing!
Time of Update: 2021-01-20
